MedTrace Logo

Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands

NCT01378845 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-12-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the prognostic influence of light rheography measurement at the fingertips from subjects with secundary Raynaud syndrome.

Conditions

  • Raynaud's Phenomenon
  • Skin Necrosis

Interventions

DRUG

Tracleer

14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o

DRUG

Prostavasin

Prostavasin 60 µg i.v, 5 days per week for 2 weeks

Sponsors & Collaborators

  • Actelion

    collaborator INDUSTRY

  • Christoph Hehrlein

    lead OTHER

Principal Investigators

  • Mark Kerber, Dr. med. · Universitätsklinik Freiburg

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2015-06-30
Completion
2015-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01378845 on ClinicalTrials.gov